Jove
Visualize
Contact Us

Related Concept Videos

Increased Intracranial Pressure l: Introduction01:14

Increased Intracranial Pressure l: Introduction

Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component expands, CSF and venous blood...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Additional Routes of Drug Administration01:18

Additional Routes of Drug Administration

Choosing the appropriate route of drug administration is significantly influenced by two key factors: the therapeutic objectives and the inherent properties of the drug being used.
Administering drugs via inhalation allows for the direct delivery of gaseous, volatile substances or droplets to different parts of the respiratory tract. One of the advantages of the inhalation route is the rapid absorption of drugs into the circulatory system, which is possible because of the large surface area of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial.

The journal of headache and pain·2026
Same author

A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US.

Cephalalgia : an international journal of headache·2026
Same author

Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trial.

Cephalalgia : an international journal of headache·2026
Same author

Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine prevention.

NPJ digital medicine·2026
Same author

Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial.

Neurology·2026
Same author

Correction: Diagnosis challenges and accessibility barriers to migraine management in Southeast Asia: results from the South-East Asia Local breAch on MigraiNe Treatment (SEALANT) study.

The journal of headache and pain·2026
Same journal

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case-control study.

Headache·2026
Same journal

Thiamine deficiency in patients with chronic migraine: A case-control study.

Headache·2026
Same journal

Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.

Headache·2026
Same journal

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Headache·2026
Same journal

Adverse childhood experiences, migraine, and adverse pregnancy outcomes among teenage mothers.

Headache·2026
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 22, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Advanced interventions for headache.

Stewart J Tepper1

  • 1Headache Center, Cleveland Clinic, Cleveland, OH 44195, USA. sjtepper@gmail.com

Headache
|May 1, 2012
PubMed
Summary
This summary is machine-generated.

For severe headaches unresponsive to oral medications, prioritize accurate diagnosis, onabotulinumtoxinA for chronic migraine, and medication overuse headache (MOH) detoxification. These steps are crucial before considering advanced treatments for better patient outcomes.

More Related Videos

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Related Experiment Videos

Last Updated: May 22, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

Area of Science:

  • Neurology
  • Headache Medicine

Background:

  • Many patients with severe, disabling daily headaches, including chronic migraine and trigeminal autonomic cephalalgias, present with treatment-resistant conditions.
  • Standard oral preventive therapies are often inadequate, contraindicated, or not tolerated by these individuals.

Purpose of the Study:

  • To review alternative therapeutic strategies for patients with severe primary headaches who have not responded to conventional oral preventive treatments.
  • To emphasize a stepwise approach, prioritizing foundational treatments before considering more invasive or experimental interventions.

Main Methods:

  • Review of current literature and clinical guidelines for managing refractory primary headache disorders.
  • Emphasis on the "big 3" initial management steps: accurate diagnosis, onabotulinumtoxinA for chronic migraine, and medication detoxification for medication overuse headache.
  • Discussion of the role of nerve blocks, multidisciplinary programs, and neuromodulation (occipital nerve stimulation, sphenopalatine ganglion stimulation) as later-stage interventions.

Main Results:

  • Successful management of a large number of patients can be achieved by adhering to the initial "big 3" approaches.
  • Simple nerve blocks may be beneficial early on, but more invasive procedures should be deferred.
  • Absolute medication weaning, potentially requiring intravenous support, is critical for medication overuse headache, alongside initiating onabotulinumtoxinA or daily prevention.

Conclusions:

  • Accurate diagnosis and foundational treatments (onabotulinumtoxinA, MOH detoxification) are paramount before exploring advanced therapies for severe headaches.
  • Multidisciplinary headache programs offer a structured approach for complex cases.
  • Neuromodulation techniques, particularly occipital nerve and sphenopalatine ganglion stimulators, show promise but require further study.